Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.34 -0.02 (-5.59%)
Market Cap 41.40M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,535,522
Avg Vol 5,912,444
Day's Range N/A - N/A
Shares Out 115.06M
Stochastic %K 56%
Beta 0.08
Analysts Strong Sell
Price Target $4.81

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 501 8881
Fax: 408 904 6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
AlpacaD
AlpacaD Jan. 20 at 7:17 PM
$RVPH 8:38, indicates time of filming , definitely prior to the 8th Jan PR 21:00 indicates financing update in a 'couple of weeks'. Expect news this week or next. https://youtu.be/Zp4rQFojneQ?si=fokZQ_WUs1PiQnPx
0 · Reply
RyanTheScammer2
RyanTheScammer2 Jan. 20 at 5:21 PM
$RVPH @yellowdog11 completely lost all credibility on this ticker. This company sucks and is going into the ground. Anyone following that stupid dog as a voice of reason needs their head checking. Y’all got what you deserved.
0 · Reply
liondwag
liondwag Jan. 20 at 5:19 PM
$RVPH hopefully partnership comes in around $500M
0 · Reply
chet__steadman
chet__steadman Jan. 20 at 4:03 PM
$RVPH I’ve been keeping an eye on this heap, is there ANY news of a potential partnership or acquisition? Seems like a huge opportunity of either occur, given they’ve proven the drug works. 🐂/ 🐻?
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 19 at 11:27 PM
$RVPH it should read "WHAT's NOT GOING ON"
0 · Reply
Univego
Univego Jan. 19 at 6:54 PM
$RVPH https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2605689:0-rvph-brilaroxazine-delivers-strong-efficacy-and-safety-in-schizophrenia-with-nda-submission-targeted-for-2027/
0 · Reply
deson
deson Jan. 19 at 4:53 PM
$RVPH Worth of reading, again. https://dtm5com.wpcomstaging.com/2026/01/05/who-should-own-the-final-mile-in-schizophrenia-drug-development-a-case-study-in-rvph/
1 · Reply
hhsll
hhsll Jan. 19 at 11:43 AM
$RVPH is there already a timeline for the resplit?
1 · Reply
liondwag
liondwag Jan. 18 at 10:27 PM
$RVPH it’s depends on how much the partnership comes in at
0 · Reply
Sir718
Sir718 Jan. 18 at 9:47 PM
$RVPH how cooked our we?
2 · Reply
Latest News on RVPH
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Dec 29, 2025, 8:00 AM EST - 22 days ago

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Dec 23, 2025, 9:26 AM EST - 4 weeks ago

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Dec 23, 2025, 8:00 AM EST - 4 weeks ago

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 4:05 PM EST - 2 months ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Oct 7, 2025, 4:08 PM EDT - 3 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 9:26 PM EDT - 4 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Sep 18, 2025, 4:05 PM EDT - 4 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:25 PM EDT - 5 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025, 8:40 AM EDT - 7 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 8 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 10 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11, 2024, 3:37 PM EST - 1 year ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AlpacaD
AlpacaD Jan. 20 at 7:17 PM
$RVPH 8:38, indicates time of filming , definitely prior to the 8th Jan PR 21:00 indicates financing update in a 'couple of weeks'. Expect news this week or next. https://youtu.be/Zp4rQFojneQ?si=fokZQ_WUs1PiQnPx
0 · Reply
RyanTheScammer2
RyanTheScammer2 Jan. 20 at 5:21 PM
$RVPH @yellowdog11 completely lost all credibility on this ticker. This company sucks and is going into the ground. Anyone following that stupid dog as a voice of reason needs their head checking. Y’all got what you deserved.
0 · Reply
liondwag
liondwag Jan. 20 at 5:19 PM
$RVPH hopefully partnership comes in around $500M
0 · Reply
chet__steadman
chet__steadman Jan. 20 at 4:03 PM
$RVPH I’ve been keeping an eye on this heap, is there ANY news of a potential partnership or acquisition? Seems like a huge opportunity of either occur, given they’ve proven the drug works. 🐂/ 🐻?
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 19 at 11:27 PM
$RVPH it should read "WHAT's NOT GOING ON"
0 · Reply
Univego
Univego Jan. 19 at 6:54 PM
$RVPH https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2605689:0-rvph-brilaroxazine-delivers-strong-efficacy-and-safety-in-schizophrenia-with-nda-submission-targeted-for-2027/
0 · Reply
deson
deson Jan. 19 at 4:53 PM
$RVPH Worth of reading, again. https://dtm5com.wpcomstaging.com/2026/01/05/who-should-own-the-final-mile-in-schizophrenia-drug-development-a-case-study-in-rvph/
1 · Reply
hhsll
hhsll Jan. 19 at 11:43 AM
$RVPH is there already a timeline for the resplit?
1 · Reply
liondwag
liondwag Jan. 18 at 10:27 PM
$RVPH it’s depends on how much the partnership comes in at
0 · Reply
Sir718
Sir718 Jan. 18 at 9:47 PM
$RVPH how cooked our we?
2 · Reply
yellowdog11
yellowdog11 Jan. 18 at 3:41 PM
$RVPH To me it's huge news that millennium management filed a 13g saying they bought 3.2 million shares They are one of the most successful and big hedge funds in the world Have 83 billion under management and 360 employees worldwide Them buying means one of two things If they did it to cover a short position that is good news because if they thought that rvph would go bankrupt or reverse split shareholders into oblivion why would they cover at this point in time Makes no sense If they bought to take a long position that's even better obviously because they have a whole bunch of analysts who would not buy into a company that is going down To me this is big news Woof
2 · Reply
History101
History101 Jan. 17 at 7:16 PM
$RVPH good info, thanks. unfortunately, when CEO mentions a timeline, you can easily double it. He has NEVER EVER come close to hitting an announced timeline goal. ever.
1 · Reply
History101
History101 Jan. 17 at 7:08 PM
$RVPH management can get RVPH schizo drug approved by the Saudi FDA right now using only the data we have right now. No ph3 required. Just like IBRX recently did. Look how the stock market recently rewarded IBRX when IBRX got the Saudis to approve their lung cancer drug.
1 · Reply
Cold_in_the_North
Cold_in_the_North Jan. 17 at 4:07 PM
$RVPH https://s3.amazonaws.com/sec.irpass.cc/2805/0001104659-26-004596.htm
1 · Reply
DistributionEquity
DistributionEquity Jan. 16 at 10:43 PM
$RVPH Summary of Information provided by Dr Bhat at the recent Lytham Partners conference. Regulatory update: ~ FDA reviewed the full dataset at a pre-NDA meeting. ~ No negative comments on existing data. ~ FDA recommended one additional Phase 3 trial to support an NDA. ~ Reviva plans to start the new trial in early Q2 2026, complete it mid-2027, and submit an NDA in Q4 2027. Financial update: ~$12M cash on hand. ~$50M additional capital required to complete the trial and NDA. ~ Management expects to provide financing updates within the next couple of weeks.
2 · Reply
Vito99
Vito99 Jan. 16 at 10:18 PM
$RVPH Bhat has just won an award for masterfully fleecing capitalists
3 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 16 at 7:14 PM
$RVPH the presentation was no different from the last several ones he gave, in fact the moderator Ben Shamsian, Vice President, Lytham Partners, cut him off short this time.
0 · Reply
liondwag
liondwag Jan. 16 at 5:14 PM
$RVPH this is a direct quote from Bhat I don’t make things up like other people
1 · Reply
liondwag
liondwag Jan. 16 at 5:12 PM
$RVPH unlike other people I didn’t say this baseless if u listened the presentation yesterday you’d understand
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 16 at 5:00 PM
$RVPH I hope they know what they are investing in?
1 · Reply
yellowdog11
yellowdog11 Jan. 16 at 4:37 PM
$RVPH The wait should be over here soon Excellent drug according to all the testing but they don't have the 60 million obviously to get phase test done and he can't dilute enough imo to raise that kind of money so I don't think bhatt has much choice but to do a partnership or get bought out woof
2 · Reply
Greenfrog3268
Greenfrog3268 Jan. 16 at 3:30 PM
$RVPH any potential for a buyout?
1 · Reply